The amplification of HER2 most frequently occurs in the rectum and then other parts of the colon, and it has been associated with acquiring resistance to EGFR-targeted therapies and shorter overall survival compared to HER2 wild-type CRC [7]. The gene discussed is ERBB2; the disease is colorectal carcinoma.